AGER and Alzheimer disease: Azeliragon (TTP488), an oral RAGE antagonist, progressed to Phase III trials for mild AD, after promising Phase II results, but failed to meet primary endpoints in the larger (STEADFAST) trial, though a diabetic subgroup showed cognitive benefits [70].